Aflibercept for diabetic macular edema

被引：0

作者：

Udaondo, Patricia ^{[1
]}

Garcia-Delpech, Salvador ^{[1
]}

Matinez-Costa, Rafael ^{[1
]}

Navarro-Piera, Juan ^{[2
]}

Cisneros-Lanuza, Angel ^{[1
]}

机构：

[1] La Fe Univ & Polytech Hosp, Valencia, Spain

[2] Francesc Borja Hosp, Gandia, Spain

来源：

EXPERT REVIEW OF OPHTHALMOLOGY | 2014年 / 9卷 / 04期

关键词：

aflibercept; anti-VEGF; avastin; intravitreal injection; laser; macula; macular degeneration; macular edema; anibizumab; retina;

D O I：

10.1586/17469899.2014.931809

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Different intravitreal anti-VEGF medications have been used for the management of retinal vascular disorders with highly satisfactory results and good safety profiles. Aflibercept, a new anti-VEGF drug with a different mechanism of action compared with prior therapies, has recently emerged. The results of aflibercept Phase II and III studies show its efficacy for the treatment of wet age-related macular degeneration, macular edema secondary to central retinal vein occlusion and diabetic macular edema.

引用

页码：263 / 268

页数：6

共 50 条

[1] Aflibercept in diabetic Macular Edema
不详
OPHTHALMOLOGE, 2015, 112 (04): : 311 - 311
[2] Intravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, Jean-Francois
Do, Diana V.
Schmidt-Erfurth, Ursula
Boyer, David S.
Holz, Frank G.
Heier, Jeffrey S.
Midena, Edoardo
Kaiser, Peter K.
Terasaki, Hiroko
Marcus, Dennis M.
Nguyen, Quan D.
Jaffe, Glenn J.
Slakter, Jason S.
Simader, Christian
Soo, Yuhwen
Schmelter, Thomas
Yancopoulos, George D.
Stahl, Neil
Vitti, Robert
Berliner, Alyson J.
Zeitz, Oliver
Metzig, Carola
Brown, David M.
OPHTHALMOLOGY, 2014, 121 (11) : 2247 - 2254
[3] Aflibercept for the treatment of diabetic macular edema
Harkins, Keegan A.
Haschke, Mary
Do, Diana V.
IMMUNOTHERAPY, 2016, 8 (05) : 503 - 510
[4] Aflibercept (Eylea®) for Refractory Diabetic Macular Edema
Jeng, Karen W.
Budoff, Greg
Fine, Howard F.
Roth, Daniel B.
Prenner, Jonathan
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
[5] The role of aflibercept in the management of diabetic macular edema
Chang, Andrew A.
Hong, Thomas
Ewe, Shaun Y.
Bahrami, Bobak
Broadhead, Geoffrey K.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4389 - 4396
[6] Aflibercept compared with dexamethasone in diabetic macular edema
Garreton, Rodolfo
Gonzalez, Raul
MEDWAVE, 2021, 21 (04):
[7] Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Wells, John A.
Glassman, Adam R.
Ayala, Allison R.
Jampol, Lee M.
Aiello, Lloyd Paul
Antoszyk, Andrew N.
Arnold-Bush, Bambi
Baker, Carl W.
Bressler, Neil M.
Browning, David J.
Elman, Michael J.
Ferris, Frederick L.
Friedman, Scott M.
Melia, Michele
Pieramici, Dante J.
Sun, Jennifer K.
Beck, Roy W.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (13): : 1193 - 1203
[8] The clinical utility of aflibercept for diabetic macular edema
Stewart, Michael W.
DIABETES METABOLIC SYNDROME AND OBESITY, 2015, 8 : 473 - 482
[9] Use Of Aflibercept (Zaltrap ZIV) in Diabetic Macular Edema
Romo-Garcia, Efrain
Meza Anguiano, Alonso
Paz Camacho, Silvia
Gutierrez, Gilberto
Quinonez, Wilehaldo
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[10] The efficacy and safety of aflibercept and conbercept in diabetic macular edema
Cai, Siwei
Yang, Qianhui
Li, Xiaorong
Zhang, Yan
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3471 - 3483

← 1 2 3 4 5 →